Macitentan denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for macitentan are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Macitentan — And How to Appeal a Denial

Macitentan is a specialty medication for pulmonary arterial hypertension (PAH), and Aetna requires prior authorization before dispensing it. A prior-authorization denial means that at the time of the initial request, the submitted clinical documentation did not satisfy one or more of the criteria in Aetna's clinical policy bulletin for macitentan. The most common gaps include insufficient documentation of the PAH diagnosis, missing functional class or severity assessment, absent prior treatment history, or failure to address formulary alternative requirements.

This is one of the most reversible denial types. Because the denial is documentation-driven, a well-prepared appeal that directly addresses each of Aetna's stated criteria has a high likelihood of reversal.

## Why This Denial Is Appealable

Aetna's prior-authorization criteria must be grounded in clinical evidence and applied consistently with its published policy. If your clinical situation meets the criteria and you can demonstrate that with complete records, the denial should not stand. Your PAH specialist is a critical partner in the appeal — their letter should speak directly to each requirement in Aetna's policy.

## Federal Appeal Framework

• Internal appeal: File within the timeframe in the denial letter. For a PAH patient whose condition is urgent or worsening, request expedited review — Aetna must respond within 72 hours.
• External review (ACA §2719): After exhausting the internal appeal, an independent IRO external review is available, generally within four months of the final internal denial.
• Expedited external review: Available for urgent situations alongside expedited internal appeal.
• ERISA §503: Employer-sponsored plans must conduct a full-and-fair review of all submitted clinical evidence, including new documentation not in the original PA request.

## Documentation to Gather

• PAH diagnosis confirmation: right heart catheterization report and supporting workup confirming the PAH diagnosis and classification
• WHO functional class assessment: current functional status documented by your specialist
• Objective severity measures: six-minute walk test results, echocardiogram data, and other chart-based measures of disease burden
• Prior treatment history: a chronological record of all prior PAH therapies — medication names, start dates, doses titrated, clinical response, and reason for the current treatment decision
• Formulary alternative documentation: if Aetna requires prior trial of formulary alternatives, document any trials completed, adverse effects, or clinical contraindications
• Prescriber medical-necessity letter: from your PAH specialist, directly addressing each criterion in Aetna's clinical policy bulletin for macitentan, citing specific chart findings and dates
• Aetna's current coverage policy: download the applicable clinical policy bulletin and use it as a checklist to ensure your submission is complete

## Criteria-Mapping Structure

For each requirement in Aetna's policy bulletin, write a direct response citing the specific chart document, date, and finding that satisfies it. This point-by-point format — with all referenced records attached as labeled exhibits — is the most effective structure for prior-authorization appeals and gives Aetna's clinical reviewers everything they need to reverse the denial.